187 related articles for article (PubMed ID: 37055433)
1. Priming a vascular-selective cytokine response permits CD8
Kim DJ; Anandh S; Null JL; Przanowski P; Bhatnagar S; Kumar P; Shelton SE; Grundy EE; Chiappinelli KB; Kamm RD; Barbie DA; Dudley AC
Nat Commun; 2023 Apr; 14(1):2122. PubMed ID: 37055433
[TBL] [Abstract][Full Text] [Related]
2. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
3. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
[TBL] [Abstract][Full Text] [Related]
5. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors.
Rosenblum JM; Shimoda N; Schenk AD; Zhang H; Kish DD; Keslar K; Farber JM; Fairchild RL
J Immunol; 2010 Apr; 184(7):3450-60. PubMed ID: 20194716
[TBL] [Abstract][Full Text] [Related]
6. Targeting KDM4C enhances CD8
Jie X; Chen Y; Zhao Y; Yang X; Xu Y; Wang J; Meng R; Zhang S; Dong X; Zhang T; Yang K; Xu S; Wu G
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121645
[TBL] [Abstract][Full Text] [Related]
7. SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells.
Carmona-Rodríguez L; Martínez-Rey D; Fernández-Aceñero MJ; González-Martín A; Paz-Cabezas M; Rodríguez-Rodríguez N; Pérez-Villamil B; Sáez ME; Díaz-Rubio E; Mira E; Mañes S
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591431
[TBL] [Abstract][Full Text] [Related]
8. LINC00152 mediates CD8
Ou J; Lei P; Yang Z; Yang M; Luo L; Mo H; Luo G; He J
J Mol Histol; 2021 Jun; 52(3):611-620. PubMed ID: 33709190
[TBL] [Abstract][Full Text] [Related]
9. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
12. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G
Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212
[TBL] [Abstract][Full Text] [Related]
13. STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.
Yue C; Shen S; Deng J; Priceman SJ; Li W; Huang A; Yu H
Cancer Immunol Res; 2015 Aug; 3(8):864-870. PubMed ID: 26025380
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy enhances CXCR3
Wang CL; Ho AS; Chang CC; Sie ZL; Peng CL; Chang J; Cheng CC
Cancer Immunol Immunother; 2023 Jun; 72(6):1865-1880. PubMed ID: 36688994
[TBL] [Abstract][Full Text] [Related]
15. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8
Li A; Chang Y; Song NJ; Wu X; Chung D; Riesenberg BP; Velegraki M; Giuliani GD; Das K; Okimoto T; Kwon H; Chakravarthy KB; Bolyard C; Wang Y; He K; Gatti-Mays M; Das J; Yang Y; Gewirth DT; Ma Q; Carbone D; Li Z
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096533
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma.
Hong YK; Li Y; Pandit H; Li S; Pulliam Z; Zheng Q; Yu Y; Martin RCG
Cell Immunol; 2019 Feb; 336():66-74. PubMed ID: 30626493
[TBL] [Abstract][Full Text] [Related]
17. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Karin N
Front Immunol; 2020; 11():976. PubMed ID: 32547545
[TBL] [Abstract][Full Text] [Related]
18. TGFβ suppresses CD8
Gunderson AJ; Yamazaki T; McCarty K; Fox N; Phillips M; Alice A; Blair T; Whiteford M; O'Brien D; Ahmad R; Kiely MX; Hayman A; Crocenzi T; Gough MJ; Crittenden MR; Young KH
Nat Commun; 2020 Apr; 11(1):1749. PubMed ID: 32273499
[TBL] [Abstract][Full Text] [Related]
19. PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma.
Tao H; Jin C; Zhou L; Deng Z; Li X; Dang W; Fan S; Li B; Ye F; Lu J; Kong X; Liu C; Luo C; Zhang Y
Cancer Res; 2024 Feb; 84(3):419-433. PubMed ID: 37991725
[TBL] [Abstract][Full Text] [Related]
20. Exercise Training Improves Tumor Control by Increasing CD8
Gomes-Santos IL; Amoozgar Z; Kumar AS; Ho WW; Roh K; Talele NP; Curtis H; Kawaguchi K; Jain RK; Fukumura D
Cancer Immunol Res; 2021 Jul; 9(7):765-778. PubMed ID: 33839688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
